MorphoSys has filed a patent for novel antibodies targeting human C5aR, with potential applications in treating inflammatory, autoimmune diseases, and cancer. The claim specifies amino acid sequences for the antibody fragments. GlobalData’s report on MorphoSys gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights MorphoSys AG - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MorphoSys, Personalized cancer vaccines was a key innovation area identified from patents. MorphoSys's grant share as of January 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies for treating inflammatory, autoimmune diseases, or cancer

Source: United States Patent and Trademark Office (USPTO). Credit: MorphoSys AG

A recently filed patent (Publication Number: US20240018225A1) discloses an isolated antibody or antigen-binding fragment specific for human C5aR. The antibody comprises specific amino acid sequences in its heavy and light chains, with variations allowed based on identity percentages to reference sequences. The patent also covers the antibody's isotype, Fc region variants, lack of effector function induction, specificity for human and cynomolgus monkey C5aR, monoclonality, and humanized or chimeric forms.

Furthermore, the patent includes claims for nucleic acid molecules encoding the antibody, vectors containing these molecules, host cells expressing the antibody, pharmaceutical compositions with the antibody and a carrier, and methods for treating diseases associated with C5aR presence. The diseases mentioned range from autoimmune and inflammatory conditions like rheumatoid arthritis and lupus to neurodegenerative disorders such as Alzheimer's Disease and Huntington's Chorea. The treatment methods involve administering the antibody alone or in combination with other therapeutic agents to address the underlying disease or disorder effectively. Additionally, a method for producing the isolated antibody is outlined, detailing the steps of obtaining a host cell with the necessary nucleic acid molecules and expressing the antibody with specific amino acid sequences in its CDRs.

To know more about GlobalData’s detailed insights on MorphoSys, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies